Observational findings suggest that prophylactic antiviral therapy may not be necessary for aplastic anemia patients with HBV, highlighting the need for close monitoring.
Overall, AA patients with chronic HBV infection need to receive prophylactic antiviral drugs during IST, while stringent surveillance methods are necessary for patients with resolved HBV infection.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: